Inovio’s novel platform for developing DNA based vaccines to be discussed at EmTech

Sep 16 2009

Inovio Biomedical Corporation (NYSE Amex:INO), a leader in DNA vaccine design, development and delivery, announced today that Dr. J. Joseph Kim, CEO, has been invited to present at EmTech, the Emerging Technologies Conference hosted by MIT and produced by MIT’s Technology Review magazine. The conference will take place September 22nd - 24th on the MIT campus in Cambridge, MA. Dr. Kim will present during a session at 9:35 a.m. - 10:45 a.m. on Wednesday, Sept. 23, in the Kresge Auditorium.

Dr. Kim will discuss Inovio’s novel platform for developing and delivering “universal” DNA-based vaccines against diseases such as human papillomavirus, hepatitis C virus, HIV, and influenza. Inovio’s universal vaccines have shown preclinical results indicating their ability to protect against new, unmatched strains of an infectious disease, for example, the currently circulating H1N1 “swine flu.” Past business leaders invited to speak at MIT’s Emerging Technologies Conference include Jeffrey Immelt, CEO, General Electric; Jeff Bezos, Founder, Amazon.com; and Sophie Vandebroek, Chief Technology Officer, Xerox.

In addition to Dr. Kim, the keynote speaker of the conference’s closing session on Tuesday, Sept. 22, will be Dr. Robert S. Langer, who serves on Inovio’s scientific advisory board and is a professor of chemical and biomedical engineering at MIT. Dr. Langer served as a member of the United States Food and Drug Administration’s SCIENCE Board, the FDA’s highest advisory board, from 1995-2002 and as its Chairman from 1999-2002.

 http://www.inovio.com/